nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—ABCB1—Lisinopril—systemic scleroderma	0.0867	0.328	CbGbCtD
Carfilzomib—ABCB1—Captopril—systemic scleroderma	0.0649	0.246	CbGbCtD
Carfilzomib—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0511	0.193	CbGbCtD
Carfilzomib—ABCB1—Prednisone—systemic scleroderma	0.0409	0.155	CbGbCtD
Carfilzomib—ABCB1—Methotrexate—systemic scleroderma	0.0205	0.0776	CbGbCtD
Carfilzomib—PSMB10—digestive system—systemic scleroderma	0.0108	0.0914	CbGeAlD
Carfilzomib—PSMB10—lung—systemic scleroderma	0.00905	0.0763	CbGeAlD
Carfilzomib—PSMB5—smooth muscle tissue—systemic scleroderma	0.00781	0.0659	CbGeAlD
Carfilzomib—PSMB2—connective tissue—systemic scleroderma	0.00728	0.0614	CbGeAlD
Carfilzomib—PSMB1—smooth muscle tissue—systemic scleroderma	0.00683	0.0576	CbGeAlD
Carfilzomib—PSMB1—skin of body—systemic scleroderma	0.00674	0.0568	CbGeAlD
Carfilzomib—PSMB2—smooth muscle tissue—systemic scleroderma	0.00666	0.0562	CbGeAlD
Carfilzomib—PSMB8—tendon—systemic scleroderma	0.00665	0.056	CbGeAlD
Carfilzomib—PSMB2—skin of body—systemic scleroderma	0.00658	0.0554	CbGeAlD
Carfilzomib—PSMB5—tendon—systemic scleroderma	0.00587	0.0495	CbGeAlD
Carfilzomib—PSMB8—lung—systemic scleroderma	0.00583	0.0492	CbGeAlD
Carfilzomib—PSMB1—digestive system—systemic scleroderma	0.00539	0.0455	CbGeAlD
Carfilzomib—PSMB2—digestive system—systemic scleroderma	0.00526	0.0443	CbGeAlD
Carfilzomib—PSMB5—lung—systemic scleroderma	0.00515	0.0434	CbGeAlD
Carfilzomib—PSMB1—tendon—systemic scleroderma	0.00513	0.0433	CbGeAlD
Carfilzomib—PSMB2—tendon—systemic scleroderma	0.00501	0.0422	CbGeAlD
Carfilzomib—PSMB1—lung—systemic scleroderma	0.0045	0.038	CbGeAlD
Carfilzomib—PSMB2—lung—systemic scleroderma	0.00439	0.037	CbGeAlD
Carfilzomib—PSMB9—Betamethasone—Mometasone—systemic scleroderma	0.0024	0.187	CbGdCrCtD
Carfilzomib—PSMB9—Dexamethasone—Mometasone—systemic scleroderma	0.0024	0.187	CbGdCrCtD
Carfilzomib—ABCB1—blood vessel—systemic scleroderma	0.00217	0.0183	CbGeAlD
Carfilzomib—Hyperglycaemia—Leflunomide—systemic scleroderma	0.00141	0.00422	CcSEcCtD
Carfilzomib—Pneumonia—Leflunomide—systemic scleroderma	0.0014	0.0042	CcSEcCtD
Carfilzomib—Neutropenia—Mycophenolic acid—systemic scleroderma	0.0014	0.00418	CcSEcCtD
Carfilzomib—Thrombocytopenia—Pentoxifylline—systemic scleroderma	0.0014	0.00418	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Mycophenolic acid—systemic scleroderma	0.00139	0.00415	CcSEcCtD
Carfilzomib—Renal failure—Leflunomide—systemic scleroderma	0.00137	0.00411	CcSEcCtD
Carfilzomib—Hyponatraemia—Mycophenolate mofetil—systemic scleroderma	0.00137	0.0041	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Leflunomide—systemic scleroderma	0.00137	0.00409	CcSEcCtD
Carfilzomib—Anorexia—Pentoxifylline—systemic scleroderma	0.00136	0.00406	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Mometasone—systemic scleroderma	0.00136	0.106	CbGdCrCtD
Carfilzomib—Hyperglycaemia—Mycophenolic acid—systemic scleroderma	0.00135	0.00403	CcSEcCtD
Carfilzomib—Pneumonia—Mycophenolic acid—systemic scleroderma	0.00134	0.00401	CcSEcCtD
Carfilzomib—Cough—Mometasone—systemic scleroderma	0.00132	0.00393	CcSEcCtD
Carfilzomib—Renal failure—Mycophenolic acid—systemic scleroderma	0.00131	0.00392	CcSEcCtD
Carfilzomib—PSMB9—Dexamethasone—Prednisone—systemic scleroderma	0.00131	0.102	CbGdCrCtD
Carfilzomib—PSMB9—Betamethasone—Prednisone—systemic scleroderma	0.00131	0.102	CbGdCrCtD
Carfilzomib—Neuropathy peripheral—Mycophenolic acid—systemic scleroderma	0.00131	0.00391	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Pentoxifylline—systemic scleroderma	0.0013	0.00388	CcSEcCtD
Carfilzomib—Cardiac arrest—Mycophenolate mofetil—systemic scleroderma	0.0013	0.00388	CcSEcCtD
Carfilzomib—Insomnia—Pentoxifylline—systemic scleroderma	0.00129	0.00386	CcSEcCtD
Carfilzomib—Arthralgia—Mometasone—systemic scleroderma	0.00128	0.00384	CcSEcCtD
Carfilzomib—Blood creatinine increased—Mycophenolate mofetil—systemic scleroderma	0.00128	0.00382	CcSEcCtD
Carfilzomib—Dyspnoea—Pentoxifylline—systemic scleroderma	0.00127	0.0038	CcSEcCtD
Carfilzomib—Neutropenia—Lisinopril—systemic scleroderma	0.00126	0.00376	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Lisinopril—systemic scleroderma	0.00125	0.00374	CcSEcCtD
Carfilzomib—Hypokalaemia—Mycophenolate mofetil—systemic scleroderma	0.00124	0.00371	CcSEcCtD
Carfilzomib—Decreased appetite—Pentoxifylline—systemic scleroderma	0.00124	0.00371	CcSEcCtD
Carfilzomib—Oedema peripheral—Leflunomide—systemic scleroderma	0.00123	0.00369	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Mycophenolate mofetil—systemic scleroderma	0.00123	0.00367	CcSEcCtD
Carfilzomib—Anaemia—Captopril—systemic scleroderma	0.00122	0.00366	CcSEcCtD
Carfilzomib—Infection—Mometasone—systemic scleroderma	0.00122	0.00366	CcSEcCtD
Carfilzomib—Constipation—Pentoxifylline—systemic scleroderma	0.00122	0.00365	CcSEcCtD
Carfilzomib—Hyperglycaemia—Lisinopril—systemic scleroderma	0.00121	0.00363	CcSEcCtD
Carfilzomib—Pneumonia—Lisinopril—systemic scleroderma	0.00121	0.00361	CcSEcCtD
Carfilzomib—Chills—Azathioprine—systemic scleroderma	0.00119	0.00356	CcSEcCtD
Carfilzomib—Hypoaesthesia—Mycophenolic acid—systemic scleroderma	0.00119	0.00356	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Lisinopril—systemic scleroderma	0.00118	0.00354	CcSEcCtD
Carfilzomib—Renal failure—Lisinopril—systemic scleroderma	0.00118	0.00353	CcSEcCtD
Carfilzomib—Oedema peripheral—Mycophenolic acid—systemic scleroderma	0.00118	0.00352	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Lisinopril—systemic scleroderma	0.00118	0.00352	CcSEcCtD
Carfilzomib—Anorexia—Mometasone—systemic scleroderma	0.00117	0.00351	CcSEcCtD
Carfilzomib—Cardiac disorder—Leflunomide—systemic scleroderma	0.00116	0.00348	CcSEcCtD
Carfilzomib—Cough—Captopril—systemic scleroderma	0.00116	0.00346	CcSEcCtD
Carfilzomib—Arthralgia—Captopril—systemic scleroderma	0.00113	0.00337	CcSEcCtD
Carfilzomib—Body temperature increased—Pentoxifylline—systemic scleroderma	0.00113	0.00337	CcSEcCtD
Carfilzomib—Chills—Leflunomide—systemic scleroderma	0.00112	0.00336	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Mometasone—systemic scleroderma	0.00112	0.00335	CcSEcCtD
Carfilzomib—Cardiac disorder—Mycophenolic acid—systemic scleroderma	0.00111	0.00332	CcSEcCtD
Carfilzomib—Sepsis—Prednisone—systemic scleroderma	0.00111	0.00331	CcSEcCtD
Carfilzomib—Neutropenia—Mycophenolate mofetil—systemic scleroderma	0.0011	0.0033	CcSEcCtD
Carfilzomib—Dyspnoea—Mometasone—systemic scleroderma	0.0011	0.00328	CcSEcCtD
Carfilzomib—Chills—Mycophenolic acid—systemic scleroderma	0.00107	0.00321	CcSEcCtD
Carfilzomib—Decreased appetite—Mometasone—systemic scleroderma	0.00107	0.0032	CcSEcCtD
Carfilzomib—Anaemia—Azathioprine—systemic scleroderma	0.00107	0.00319	CcSEcCtD
Carfilzomib—Hyperglycaemia—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00318	CcSEcCtD
Carfilzomib—Oedema peripheral—Lisinopril—systemic scleroderma	0.00106	0.00317	CcSEcCtD
Carfilzomib—Fatigue—Mometasone—systemic scleroderma	0.00106	0.00317	CcSEcCtD
Carfilzomib—Thrombocytopenia—Captopril—systemic scleroderma	0.00106	0.00316	CcSEcCtD
Carfilzomib—Pneumonia—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00316	CcSEcCtD
Carfilzomib—Back pain—Leflunomide—systemic scleroderma	0.00106	0.00316	CcSEcCtD
Carfilzomib—Pain—Mometasone—systemic scleroderma	0.00105	0.00315	CcSEcCtD
Carfilzomib—Muscle spasms—Leflunomide—systemic scleroderma	0.00105	0.00314	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Mycophenolate mofetil—systemic scleroderma	0.00104	0.0031	CcSEcCtD
Carfilzomib—Leukopenia—Azathioprine—systemic scleroderma	0.00103	0.00309	CcSEcCtD
Carfilzomib—PSMB8—Diflorasone—Mometasone—systemic scleroderma	0.00103	0.0806	CbGdCrCtD
Carfilzomib—Renal failure—Mycophenolate mofetil—systemic scleroderma	0.00103	0.00309	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Mycophenolate mofetil—systemic scleroderma	0.00103	0.00308	CcSEcCtD
Carfilzomib—Anorexia—Captopril—systemic scleroderma	0.00103	0.00308	CcSEcCtD
Carfilzomib—Asthenia—Pentoxifylline—systemic scleroderma	0.00102	0.00306	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Prednisone—systemic scleroderma	0.00102	0.00305	CcSEcCtD
Carfilzomib—Anaemia—Leflunomide—systemic scleroderma	0.00101	0.00302	CcSEcCtD
Carfilzomib—Back pain—Mycophenolic acid—systemic scleroderma	0.00101	0.00301	CcSEcCtD
Carfilzomib—Muscle spasms—Mycophenolic acid—systemic scleroderma	0.001	0.00299	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Captopril—systemic scleroderma	0.000984	0.00294	CcSEcCtD
Carfilzomib—Arthralgia—Azathioprine—systemic scleroderma	0.000984	0.00294	CcSEcCtD
Carfilzomib—Insomnia—Captopril—systemic scleroderma	0.000977	0.00292	CcSEcCtD
Carfilzomib—Leukopenia—Leflunomide—systemic scleroderma	0.000977	0.00292	CcSEcCtD
Carfilzomib—Diarrhoea—Pentoxifylline—systemic scleroderma	0.000975	0.00292	CcSEcCtD
Carfilzomib—Body temperature increased—Mometasone—systemic scleroderma	0.000972	0.00291	CcSEcCtD
Carfilzomib—Chills—Lisinopril—systemic scleroderma	0.000966	0.00289	CcSEcCtD
Carfilzomib—Dyspnoea—Captopril—systemic scleroderma	0.000963	0.00288	CcSEcCtD
Carfilzomib—Anaemia—Mycophenolic acid—systemic scleroderma	0.000962	0.00288	CcSEcCtD
Carfilzomib—Cough—Leflunomide—systemic scleroderma	0.000952	0.00285	CcSEcCtD
Carfilzomib—Dizziness—Pentoxifylline—systemic scleroderma	0.000943	0.00282	CcSEcCtD
Carfilzomib—Hypertension—Leflunomide—systemic scleroderma	0.000942	0.00282	CcSEcCtD
Carfilzomib—Decreased appetite—Captopril—systemic scleroderma	0.000939	0.00281	CcSEcCtD
Carfilzomib—Hypoaesthesia—Mycophenolate mofetil—systemic scleroderma	0.000939	0.00281	CcSEcCtD
Carfilzomib—Infection—Azathioprine—systemic scleroderma	0.000937	0.0028	CcSEcCtD
Carfilzomib—Leukopenia—Mycophenolic acid—systemic scleroderma	0.000932	0.00279	CcSEcCtD
Carfilzomib—Fatigue—Captopril—systemic scleroderma	0.000931	0.00279	CcSEcCtD
Carfilzomib—Oedema peripheral—Mycophenolate mofetil—systemic scleroderma	0.000929	0.00278	CcSEcCtD
Carfilzomib—Arthralgia—Leflunomide—systemic scleroderma	0.000929	0.00278	CcSEcCtD
Carfilzomib—Constipation—Captopril—systemic scleroderma	0.000924	0.00276	CcSEcCtD
Carfilzomib—Sepsis—Methotrexate—systemic scleroderma	0.000924	0.00276	CcSEcCtD
Carfilzomib—Thrombocytopenia—Azathioprine—systemic scleroderma	0.000923	0.00276	CcSEcCtD
Carfilzomib—Cough—Mycophenolic acid—systemic scleroderma	0.000908	0.00272	CcSEcCtD
Carfilzomib—Back pain—Lisinopril—systemic scleroderma	0.000907	0.00271	CcSEcCtD
Carfilzomib—Vomiting—Pentoxifylline—systemic scleroderma	0.000906	0.00271	CcSEcCtD
Carfilzomib—Muscle spasms—Lisinopril—systemic scleroderma	0.000901	0.0027	CcSEcCtD
Carfilzomib—Hypertension—Mycophenolic acid—systemic scleroderma	0.000899	0.00269	CcSEcCtD
Carfilzomib—Headache—Pentoxifylline—systemic scleroderma	0.000893	0.00267	CcSEcCtD
Carfilzomib—Arthralgia—Mycophenolic acid—systemic scleroderma	0.000886	0.00265	CcSEcCtD
Carfilzomib—Infection—Leflunomide—systemic scleroderma	0.000885	0.00265	CcSEcCtD
Carfilzomib—Asthenia—Mometasone—systemic scleroderma	0.000882	0.00264	CcSEcCtD
Carfilzomib—Cardiac arrest—Prednisone—systemic scleroderma	0.000879	0.00263	CcSEcCtD
Carfilzomib—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.000876	0.00262	CcSEcCtD
Carfilzomib—Thrombocytopenia—Leflunomide—systemic scleroderma	0.000872	0.00261	CcSEcCtD
Carfilzomib—Anaemia—Lisinopril—systemic scleroderma	0.000866	0.00259	CcSEcCtD
Carfilzomib—Hepatic failure—Methotrexate—systemic scleroderma	0.00086	0.00257	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000859	0.00257	CcSEcCtD
Carfilzomib—Body temperature increased—Captopril—systemic scleroderma	0.000854	0.00255	CcSEcCtD
Carfilzomib—Anorexia—Leflunomide—systemic scleroderma	0.000849	0.00254	CcSEcCtD
Carfilzomib—Nausea—Pentoxifylline—systemic scleroderma	0.000847	0.00253	CcSEcCtD
Carfilzomib—Chills—Mycophenolate mofetil—systemic scleroderma	0.000847	0.00253	CcSEcCtD
Carfilzomib—Infection—Mycophenolic acid—systemic scleroderma	0.000844	0.00252	CcSEcCtD
Carfilzomib—Diarrhoea—Mometasone—systemic scleroderma	0.000842	0.00252	CcSEcCtD
Carfilzomib—Hypokalaemia—Prednisone—systemic scleroderma	0.000841	0.00252	CcSEcCtD
Carfilzomib—Leukopenia—Lisinopril—systemic scleroderma	0.000839	0.00251	CcSEcCtD
Carfilzomib—Renal failure acute—Methotrexate—systemic scleroderma	0.000837	0.0025	CcSEcCtD
Carfilzomib—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000832	0.00249	CcSEcCtD
Carfilzomib—Cough—Lisinopril—systemic scleroderma	0.000818	0.00245	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000811	0.00243	CcSEcCtD
Carfilzomib—Anorexia—Mycophenolic acid—systemic scleroderma	0.00081	0.00242	CcSEcCtD
Carfilzomib—Insomnia—Leflunomide—systemic scleroderma	0.000805	0.00241	CcSEcCtD
Carfilzomib—ABCB1—digestive system—systemic scleroderma	0.000804	0.00678	CbGeAlD
Carfilzomib—Arthralgia—Lisinopril—systemic scleroderma	0.000798	0.00239	CcSEcCtD
Carfilzomib—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000794	0.00238	CcSEcCtD
Carfilzomib—Dyspnoea—Leflunomide—systemic scleroderma	0.000794	0.00237	CcSEcCtD
Carfilzomib—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.00079	0.00236	CcSEcCtD
Carfilzomib—Vomiting—Mometasone—systemic scleroderma	0.000782	0.00234	CcSEcCtD
Carfilzomib—Asthenia—Captopril—systemic scleroderma	0.000775	0.00232	CcSEcCtD
Carfilzomib—Decreased appetite—Leflunomide—systemic scleroderma	0.000774	0.00232	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000774	0.00231	CcSEcCtD
Carfilzomib—Headache—Mometasone—systemic scleroderma	0.000771	0.0023	CcSEcCtD
Carfilzomib—Insomnia—Mycophenolic acid—systemic scleroderma	0.000768	0.0023	CcSEcCtD
Carfilzomib—Fatigue—Leflunomide—systemic scleroderma	0.000768	0.0023	CcSEcCtD
Carfilzomib—Pain—Leflunomide—systemic scleroderma	0.000761	0.00228	CcSEcCtD
Carfilzomib—Constipation—Leflunomide—systemic scleroderma	0.000761	0.00228	CcSEcCtD
Carfilzomib—Infection—Lisinopril—systemic scleroderma	0.00076	0.00227	CcSEcCtD
Carfilzomib—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000759	0.00227	CcSEcCtD
Carfilzomib—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000757	0.00227	CcSEcCtD
Carfilzomib—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000749	0.00224	CcSEcCtD
Carfilzomib—Neutropenia—Prednisone—systemic scleroderma	0.000747	0.00224	CcSEcCtD
Carfilzomib—Body temperature increased—Azathioprine—systemic scleroderma	0.000745	0.00223	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Prednisone—systemic scleroderma	0.00074	0.0577	CbGdCrCtD
Carfilzomib—Diarrhoea—Captopril—systemic scleroderma	0.000739	0.00221	CcSEcCtD
Carfilzomib—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000738	0.00221	CcSEcCtD
Carfilzomib—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000735	0.0022	CcSEcCtD
Carfilzomib—Fatigue—Mycophenolic acid—systemic scleroderma	0.000732	0.00219	CcSEcCtD
Carfilzomib—Nausea—Mometasone—systemic scleroderma	0.000731	0.00219	CcSEcCtD
Carfilzomib—Anorexia—Lisinopril—systemic scleroderma	0.000729	0.00218	CcSEcCtD
Carfilzomib—Constipation—Mycophenolic acid—systemic scleroderma	0.000726	0.00217	CcSEcCtD
Carfilzomib—Pain—Mycophenolic acid—systemic scleroderma	0.000726	0.00217	CcSEcCtD
Carfilzomib—Hyperglycaemia—Prednisone—systemic scleroderma	0.000721	0.00216	CcSEcCtD
Carfilzomib—Cough—Mycophenolate mofetil—systemic scleroderma	0.000717	0.00214	CcSEcCtD
Carfilzomib—Dizziness—Captopril—systemic scleroderma	0.000714	0.00214	CcSEcCtD
Carfilzomib—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000709	0.00212	CcSEcCtD
Carfilzomib—Body temperature increased—Leflunomide—systemic scleroderma	0.000704	0.00211	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000702	0.0021	CcSEcCtD
Carfilzomib—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000699	0.00209	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000698	0.00209	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000697	0.00209	CcSEcCtD
Carfilzomib—Insomnia—Lisinopril—systemic scleroderma	0.000692	0.00207	CcSEcCtD
Carfilzomib—Vomiting—Captopril—systemic scleroderma	0.000687	0.00205	CcSEcCtD
Carfilzomib—Dyspnoea—Lisinopril—systemic scleroderma	0.000682	0.00204	CcSEcCtD
Carfilzomib—Headache—Captopril—systemic scleroderma	0.000677	0.00202	CcSEcCtD
Carfilzomib—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000671	0.00201	CcSEcCtD
Carfilzomib—ABCB1—lung—systemic scleroderma	0.000671	0.00566	CbGeAlD
Carfilzomib—Infection—Mycophenolate mofetil—systemic scleroderma	0.000666	0.00199	CcSEcCtD
Carfilzomib—Decreased appetite—Lisinopril—systemic scleroderma	0.000665	0.00199	CcSEcCtD
Carfilzomib—Fatigue—Lisinopril—systemic scleroderma	0.00066	0.00197	CcSEcCtD
Carfilzomib—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000656	0.00196	CcSEcCtD
Carfilzomib—Pain—Lisinopril—systemic scleroderma	0.000654	0.00196	CcSEcCtD
Carfilzomib—Constipation—Lisinopril—systemic scleroderma	0.000654	0.00196	CcSEcCtD
Carfilzomib—Diarrhoea—Azathioprine—systemic scleroderma	0.000645	0.00193	CcSEcCtD
Carfilzomib—Nausea—Captopril—systemic scleroderma	0.000642	0.00192	CcSEcCtD
Carfilzomib—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000639	0.00191	CcSEcCtD
Carfilzomib—Asthenia—Leflunomide—systemic scleroderma	0.000639	0.00191	CcSEcCtD
Carfilzomib—Neutropenia—Methotrexate—systemic scleroderma	0.000624	0.00187	CcSEcCtD
Carfilzomib—Dizziness—Azathioprine—systemic scleroderma	0.000623	0.00187	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000621	0.00186	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000611	0.00183	CcSEcCtD
Carfilzomib—Asthenia—Mycophenolic acid—systemic scleroderma	0.000609	0.00182	CcSEcCtD
Carfilzomib—Diarrhoea—Leflunomide—systemic scleroderma	0.000609	0.00182	CcSEcCtD
Carfilzomib—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000606	0.00181	CcSEcCtD
Carfilzomib—Body temperature increased—Lisinopril—systemic scleroderma	0.000605	0.00181	CcSEcCtD
Carfilzomib—Vomiting—Azathioprine—systemic scleroderma	0.000599	0.00179	CcSEcCtD
Carfilzomib—Pneumonia—Methotrexate—systemic scleroderma	0.000599	0.00179	CcSEcCtD
Carfilzomib—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000598	0.00179	CcSEcCtD
Carfilzomib—Headache—Azathioprine—systemic scleroderma	0.000591	0.00177	CcSEcCtD
Carfilzomib—Dizziness—Leflunomide—systemic scleroderma	0.000589	0.00176	CcSEcCtD
Carfilzomib—Renal failure—Methotrexate—systemic scleroderma	0.000585	0.00175	CcSEcCtD
Carfilzomib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000583	0.00174	CcSEcCtD
Carfilzomib—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000581	0.00174	CcSEcCtD
Carfilzomib—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000573	0.00171	CcSEcCtD
Carfilzomib—Pain—Mycophenolate mofetil—systemic scleroderma	0.000573	0.00171	CcSEcCtD
Carfilzomib—Vomiting—Leflunomide—systemic scleroderma	0.000566	0.00169	CcSEcCtD
Carfilzomib—PSMB8—Diflorasone—Prednisone—systemic scleroderma	0.000563	0.0439	CbGdCrCtD
Carfilzomib—Dizziness—Mycophenolic acid—systemic scleroderma	0.000562	0.00168	CcSEcCtD
Carfilzomib—Nausea—Azathioprine—systemic scleroderma	0.00056	0.00168	CcSEcCtD
Carfilzomib—Headache—Leflunomide—systemic scleroderma	0.000558	0.00167	CcSEcCtD
Carfilzomib—PSMB8—Betamethasone—Mometasone—systemic scleroderma	0.000554	0.0432	CbGdCrCtD
Carfilzomib—PSMB8—Dexamethasone—Mometasone—systemic scleroderma	0.000554	0.0432	CbGdCrCtD
Carfilzomib—Asthenia—Lisinopril—systemic scleroderma	0.000549	0.00164	CcSEcCtD
Carfilzomib—Vomiting—Mycophenolic acid—systemic scleroderma	0.00054	0.00162	CcSEcCtD
Carfilzomib—Headache—Mycophenolic acid—systemic scleroderma	0.000532	0.00159	CcSEcCtD
Carfilzomib—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.00053	0.00159	CcSEcCtD
Carfilzomib—Nausea—Leflunomide—systemic scleroderma	0.000529	0.00158	CcSEcCtD
Carfilzomib—Diarrhoea—Lisinopril—systemic scleroderma	0.000523	0.00157	CcSEcCtD
Carfilzomib—Anaemia—Prednisone—systemic scleroderma	0.000515	0.00154	CcSEcCtD
Carfilzomib—PSMB10—Adaptive Immune System—BLK—systemic scleroderma	0.000514	0.0019	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—BLK—systemic scleroderma	0.000511	0.00189	CbGpPWpGaD
Carfilzomib—Dizziness—Lisinopril—systemic scleroderma	0.000506	0.00151	CcSEcCtD
Carfilzomib—PSMB10—Gene Expression—SMAD7—systemic scleroderma	0.000505	0.00187	CbGpPWpGaD
Carfilzomib—Nausea—Mycophenolic acid—systemic scleroderma	0.000505	0.00151	CcSEcCtD
Carfilzomib—PSMB9—Gene Expression—SMAD7—systemic scleroderma	0.000503	0.00186	CbGpPWpGaD
Carfilzomib—Cardiac disorder—Methotrexate—systemic scleroderma	0.000496	0.00148	CcSEcCtD
Carfilzomib—Vomiting—Lisinopril—systemic scleroderma	0.000486	0.00146	CcSEcCtD
Carfilzomib—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000481	0.00144	CcSEcCtD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—HLA-DQB1—systemic scleroderma	0.000481	0.00178	CbGpPWpGaD
Carfilzomib—Hypertension—Prednisone—systemic scleroderma	0.000481	0.00144	CcSEcCtD
Carfilzomib—Chills—Methotrexate—systemic scleroderma	0.00048	0.00143	CcSEcCtD
Carfilzomib—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	0.000479	0.00177	CbGpPWpGaD
Carfilzomib—Headache—Lisinopril—systemic scleroderma	0.000479	0.00143	CcSEcCtD
Carfilzomib—Arthralgia—Prednisone—systemic scleroderma	0.000474	0.00142	CcSEcCtD
Carfilzomib—PSMB10—Gene Expression—TNFSF13—systemic scleroderma	0.00047	0.00174	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—SMAD7—systemic scleroderma	0.000469	0.00174	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—TNFSF13—systemic scleroderma	0.000468	0.00173	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—SMAD7—systemic scleroderma	0.000467	0.00173	CbGpPWpGaD
Carfilzomib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000459	0.00137	CcSEcCtD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	0.000457	0.00169	CbGpPWpGaD
Carfilzomib—Nausea—Lisinopril—systemic scleroderma	0.000454	0.00136	CcSEcCtD
Carfilzomib—Infection—Prednisone—systemic scleroderma	0.000451	0.00135	CcSEcCtD
Carfilzomib—Back pain—Methotrexate—systemic scleroderma	0.00045	0.00135	CcSEcCtD
Carfilzomib—PSMB1—Adaptive Immune System—CSK—systemic scleroderma	0.000447	0.00166	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—CSK—systemic scleroderma	0.000447	0.00166	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—CSK—systemic scleroderma	0.000447	0.00166	CbGpPWpGaD
Carfilzomib—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000443	0.00133	CcSEcCtD
Carfilzomib—PSMB8—Adaptive Immune System—CSK—systemic scleroderma	0.000441	0.00163	CbGpPWpGaD
Carfilzomib—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.000435	0.00161	CbGpPWpGaD
Carfilzomib—Anorexia—Prednisone—systemic scleroderma	0.000433	0.0013	CcSEcCtD
Carfilzomib—Anaemia—Methotrexate—systemic scleroderma	0.00043	0.00129	CcSEcCtD
Carfilzomib—PSMB10—Disease—TGFBI—systemic scleroderma	0.000429	0.00159	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—TGFBI—systemic scleroderma	0.000427	0.00158	CbGpPWpGaD
Carfilzomib—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000426	0.00127	CcSEcCtD
Carfilzomib—PSMB1—Adaptive Immune System—CD247—systemic scleroderma	0.000421	0.00156	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—CD247—systemic scleroderma	0.000421	0.00156	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—CTLA4—systemic scleroderma	0.000421	0.00156	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—CD247—systemic scleroderma	0.000421	0.00156	CbGpPWpGaD
Carfilzomib—Headache—Mycophenolate mofetil—systemic scleroderma	0.00042	0.00126	CcSEcCtD
Carfilzomib—PSMB9—Adaptive Immune System—CTLA4—systemic scleroderma	0.000419	0.00155	CbGpPWpGaD
Carfilzomib—Leukopenia—Methotrexate—systemic scleroderma	0.000416	0.00125	CcSEcCtD
Carfilzomib—PSMB8—Adaptive Immune System—CD247—systemic scleroderma	0.000415	0.00154	CbGpPWpGaD
Carfilzomib—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000414	0.00124	CcSEcCtD
Carfilzomib—Insomnia—Prednisone—systemic scleroderma	0.000411	0.00123	CcSEcCtD
Carfilzomib—Cough—Methotrexate—systemic scleroderma	0.000406	0.00121	CcSEcCtD
Carfilzomib—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000398	0.00119	CcSEcCtD
Carfilzomib—Arthralgia—Methotrexate—systemic scleroderma	0.000396	0.00118	CcSEcCtD
Carfilzomib—Decreased appetite—Prednisone—systemic scleroderma	0.000395	0.00118	CcSEcCtD
Carfilzomib—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	0.000395	0.00146	CbGpPWpGaD
Carfilzomib—Fatigue—Prednisone—systemic scleroderma	0.000392	0.00117	CcSEcCtD
Carfilzomib—PSMB5—Adaptive Immune System—BLK—systemic scleroderma	0.000389	0.00144	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—BLK—systemic scleroderma	0.000389	0.00144	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—BLK—systemic scleroderma	0.000389	0.00144	CbGpPWpGaD
Carfilzomib—Constipation—Prednisone—systemic scleroderma	0.000389	0.00116	CcSEcCtD
Carfilzomib—PSMB8—Adaptive Immune System—BLK—systemic scleroderma	0.000384	0.00142	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—SMAD7—systemic scleroderma	0.000383	0.00142	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—SMAD7—systemic scleroderma	0.000383	0.00142	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—SMAD7—systemic scleroderma	0.000383	0.00142	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—SMAD7—systemic scleroderma	0.000378	0.0014	CbGpPWpGaD
Carfilzomib—Infection—Methotrexate—systemic scleroderma	0.000377	0.00113	CcSEcCtD
Carfilzomib—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	0.000375	0.00139	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	0.000373	0.00138	CbGpPWpGaD
Carfilzomib—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000372	0.00111	CcSEcCtD
Carfilzomib—Anorexia—Methotrexate—systemic scleroderma	0.000362	0.00108	CcSEcCtD
Carfilzomib—Body temperature increased—Prednisone—systemic scleroderma	0.000359	0.00107	CcSEcCtD
Carfilzomib—PSMB10—Immune System—CSK—systemic scleroderma	0.000358	0.00133	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CSK—systemic scleroderma	0.000356	0.00132	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—TNFSF13—systemic scleroderma	0.000356	0.00132	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—TNFSF13—systemic scleroderma	0.000356	0.00132	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—TNFSF13—systemic scleroderma	0.000356	0.00132	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—SMAD7—systemic scleroderma	0.000356	0.00132	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—SMAD7—systemic scleroderma	0.000356	0.00132	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—SMAD7—systemic scleroderma	0.000356	0.00132	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IRF5—systemic scleroderma	0.000352	0.0013	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—TNFSF13—systemic scleroderma	0.000351	0.0013	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—SMAD7—systemic scleroderma	0.000351	0.0013	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IRF5—systemic scleroderma	0.000351	0.0013	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000346	0.00128	CbGpPWpGaD
Carfilzomib—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000346	0.00103	CcSEcCtD
Carfilzomib—PSMB9—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000345	0.00128	CbGpPWpGaD
Carfilzomib—Insomnia—Methotrexate—systemic scleroderma	0.000343	0.00103	CcSEcCtD
Carfilzomib—PSMB10—Disease—HSPG2—systemic scleroderma	0.000342	0.00127	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—HSPG2—systemic scleroderma	0.000341	0.00126	CbGpPWpGaD
Carfilzomib—Dyspnoea—Methotrexate—systemic scleroderma	0.000339	0.00101	CcSEcCtD
Carfilzomib—PSMB10—Immune System—IRF8—systemic scleroderma	0.000337	0.00125	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—ITGAM—systemic scleroderma	0.000337	0.00125	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—CD247—systemic scleroderma	0.000337	0.00125	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—ITGAM—systemic scleroderma	0.000335	0.00124	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CD247—systemic scleroderma	0.000335	0.00124	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IRF8—systemic scleroderma	0.000335	0.00124	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—CSK—systemic scleroderma	0.000331	0.00122	CbGpPWpGaD
Carfilzomib—Decreased appetite—Methotrexate—systemic scleroderma	0.00033	0.000987	CcSEcCtD
Carfilzomib—PSMB9—Disease—CSK—systemic scleroderma	0.000329	0.00122	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—SMAD7—systemic scleroderma	0.000329	0.00122	CbGpPWpGaD
Carfilzomib—Fatigue—Methotrexate—systemic scleroderma	0.000327	0.000979	CcSEcCtD
Carfilzomib—PSMB10—Adaptive Immune System—CD40LG—systemic scleroderma	0.000327	0.00121	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—SMAD7—systemic scleroderma	0.000327	0.00121	CbGpPWpGaD
Carfilzomib—Asthenia—Prednisone—systemic scleroderma	0.000326	0.000975	CcSEcCtD
Carfilzomib—PSMB9—Adaptive Immune System—CD40LG—systemic scleroderma	0.000326	0.00121	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—TGFBI—systemic scleroderma	0.000325	0.0012	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—TGFBI—systemic scleroderma	0.000325	0.0012	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—TGFBI—systemic scleroderma	0.000325	0.0012	CbGpPWpGaD
Carfilzomib—Pain—Methotrexate—systemic scleroderma	0.000325	0.000971	CcSEcCtD
Carfilzomib—PSMB8—Disease—TGFBI—systemic scleroderma	0.000321	0.00119	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—CTLA4—systemic scleroderma	0.000319	0.00118	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—CTLA4—systemic scleroderma	0.000319	0.00118	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—CTLA4—systemic scleroderma	0.000319	0.00118	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—TNFAIP3—systemic scleroderma	0.000315	0.00117	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—CTLA4—systemic scleroderma	0.000314	0.00116	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—TNFAIP3—systemic scleroderma	0.000314	0.00116	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—BLK—systemic scleroderma	0.000312	0.00115	CbGpPWpGaD
Carfilzomib—Diarrhoea—Prednisone—systemic scleroderma	0.000311	0.00093	CcSEcCtD
Carfilzomib—PSMB10—Disease—CD247—systemic scleroderma	0.000311	0.00115	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—BLK—systemic scleroderma	0.00031	0.00115	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—CD247—systemic scleroderma	0.000309	0.00115	CbGpPWpGaD
Carfilzomib—PSMB8—Dexamethasone—Prednisone—systemic scleroderma	0.000302	0.0236	CbGdCrCtD
Carfilzomib—PSMB8—Betamethasone—Prednisone—systemic scleroderma	0.000302	0.0236	CbGdCrCtD
Carfilzomib—Dizziness—Prednisone—systemic scleroderma	0.0003	0.000899	CcSEcCtD
Carfilzomib—Body temperature increased—Methotrexate—systemic scleroderma	0.0003	0.000898	CcSEcCtD
Carfilzomib—Vomiting—Prednisone—systemic scleroderma	0.000289	0.000864	CcSEcCtD
Carfilzomib—PSMB10—Metabolism—HSPG2—systemic scleroderma	0.000287	0.00106	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—HSPG2—systemic scleroderma	0.000285	0.00106	CbGpPWpGaD
Carfilzomib—Headache—Prednisone—systemic scleroderma	0.000285	0.000851	CcSEcCtD
Carfilzomib—PSMB10—Gene Expression—CTGF—systemic scleroderma	0.000279	0.00103	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—CTGF—systemic scleroderma	0.000278	0.00103	CbGpPWpGaD
Carfilzomib—Asthenia—Methotrexate—systemic scleroderma	0.000272	0.000815	CcSEcCtD
Carfilzomib—PSMB2—Immune System—CSK—systemic scleroderma	0.000271	0.001	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CSK—systemic scleroderma	0.000271	0.001	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CSK—systemic scleroderma	0.000271	0.001	CbGpPWpGaD
Carfilzomib—Nausea—Prednisone—systemic scleroderma	0.00027	0.000807	CcSEcCtD
Carfilzomib—PSMB8—Immune System—CSK—systemic scleroderma	0.000268	0.00099	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IRF5—systemic scleroderma	0.000267	0.000988	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IRF5—systemic scleroderma	0.000267	0.000988	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IRF5—systemic scleroderma	0.000267	0.000988	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IRF5—systemic scleroderma	0.000263	0.000974	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000263	0.000972	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000263	0.000972	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000263	0.000972	CbGpPWpGaD
Carfilzomib—Diarrhoea—Methotrexate—systemic scleroderma	0.00026	0.000777	CcSEcCtD
Carfilzomib—PSMB1—Disease—HSPG2—systemic scleroderma	0.000259	0.00096	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HSPG2—systemic scleroderma	0.000259	0.00096	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HSPG2—systemic scleroderma	0.000259	0.00096	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000259	0.000958	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HSPG2—systemic scleroderma	0.000256	0.000947	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—CTLA4—systemic scleroderma	0.000255	0.000945	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IRF8—systemic scleroderma	0.000255	0.000945	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CD247—systemic scleroderma	0.000255	0.000945	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—ITGAM—systemic scleroderma	0.000255	0.000945	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—ITGAM—systemic scleroderma	0.000255	0.000945	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IRF8—systemic scleroderma	0.000255	0.000945	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CD247—systemic scleroderma	0.000255	0.000945	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IRF8—systemic scleroderma	0.000255	0.000945	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—ITGAM—systemic scleroderma	0.000255	0.000945	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CD247—systemic scleroderma	0.000255	0.000945	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—RHOB—systemic scleroderma	0.000254	0.000941	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CTLA4—systemic scleroderma	0.000254	0.00094	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—RHOB—systemic scleroderma	0.000253	0.000937	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IRF8—systemic scleroderma	0.000252	0.000931	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—ITGAM—systemic scleroderma	0.000252	0.000931	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CD247—systemic scleroderma	0.000252	0.000931	CbGpPWpGaD
Carfilzomib—Dizziness—Methotrexate—systemic scleroderma	0.000251	0.000751	CcSEcCtD
Carfilzomib—PSMB2—Disease—CSK—systemic scleroderma	0.000251	0.000928	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—CSK—systemic scleroderma	0.000251	0.000928	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—CSK—systemic scleroderma	0.000251	0.000928	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SMAD7—systemic scleroderma	0.000249	0.000922	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SMAD7—systemic scleroderma	0.000249	0.000922	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SMAD7—systemic scleroderma	0.000249	0.000922	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—CD40LG—systemic scleroderma	0.000248	0.000918	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—CD40LG—systemic scleroderma	0.000248	0.000918	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—CD40LG—systemic scleroderma	0.000248	0.000918	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—CSK—systemic scleroderma	0.000247	0.000914	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SMAD7—systemic scleroderma	0.000246	0.000909	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—CD40LG—systemic scleroderma	0.000244	0.000905	CbGpPWpGaD
Carfilzomib—Vomiting—Methotrexate—systemic scleroderma	0.000241	0.000722	CcSEcCtD
Carfilzomib—PSMB10—Signaling Pathways—HSPG2—systemic scleroderma	0.00024	0.000887	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—TNFAIP3—systemic scleroderma	0.000239	0.000884	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—TNFAIP3—systemic scleroderma	0.000239	0.000884	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—TNFAIP3—systemic scleroderma	0.000239	0.000884	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—HSPG2—systemic scleroderma	0.000239	0.000883	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	0.000238	0.000881	CbGpPWpGaD
Carfilzomib—Headache—Methotrexate—systemic scleroderma	0.000238	0.000712	CcSEcCtD
Carfilzomib—PSMB1—Immune System—BLK—systemic scleroderma	0.000236	0.000874	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—BLK—systemic scleroderma	0.000236	0.000874	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—BLK—systemic scleroderma	0.000236	0.000874	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—CD247—systemic scleroderma	0.000236	0.000872	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—CD247—systemic scleroderma	0.000236	0.000872	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—CD247—systemic scleroderma	0.000236	0.000872	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—TNFAIP3—systemic scleroderma	0.000236	0.000872	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—BLK—systemic scleroderma	0.000233	0.000862	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—CD247—systemic scleroderma	0.000232	0.00086	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CSK—systemic scleroderma	0.000232	0.000857	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CSK—systemic scleroderma	0.00023	0.000853	CbGpPWpGaD
Carfilzomib—Nausea—Methotrexate—systemic scleroderma	0.000226	0.000675	CcSEcCtD
Carfilzomib—PSMB1—Metabolism—HSPG2—systemic scleroderma	0.000217	0.000804	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—HSPG2—systemic scleroderma	0.000217	0.000804	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—HSPG2—systemic scleroderma	0.000217	0.000804	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—CTGF—systemic scleroderma	0.000217	0.000804	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—CTGF—systemic scleroderma	0.000216	0.0008	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—HSPG2—systemic scleroderma	0.000214	0.000793	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—CTGF—systemic scleroderma	0.000212	0.000784	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—CTGF—systemic scleroderma	0.000212	0.000784	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—CTGF—systemic scleroderma	0.000212	0.000784	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—HLA-DQB1—systemic scleroderma	0.00021	0.000778	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—HLA-DQB1—systemic scleroderma	0.000209	0.000774	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—CTGF—systemic scleroderma	0.000209	0.000773	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL1A—systemic scleroderma	0.0002	0.000739	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL1A—systemic scleroderma	0.000199	0.000735	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—CD40LG—systemic scleroderma	0.000198	0.000735	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CD40LG—systemic scleroderma	0.000197	0.000731	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	0.000196	0.000724	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CTLA4—systemic scleroderma	0.000193	0.000716	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CTLA4—systemic scleroderma	0.000193	0.000716	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CTLA4—systemic scleroderma	0.000193	0.000716	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—RHOB—systemic scleroderma	0.000193	0.000713	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—RHOB—systemic scleroderma	0.000193	0.000713	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—RHOB—systemic scleroderma	0.000193	0.000713	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CTLA4—systemic scleroderma	0.000191	0.000706	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—RHOB—systemic scleroderma	0.00019	0.000703	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—HSPG2—systemic scleroderma	0.000182	0.000673	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—HSPG2—systemic scleroderma	0.000182	0.000673	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—HSPG2—systemic scleroderma	0.000182	0.000673	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—HSPG2—systemic scleroderma	0.000179	0.000663	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CSK—systemic scleroderma	0.000175	0.00065	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CSK—systemic scleroderma	0.000175	0.00065	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CSK—systemic scleroderma	0.000175	0.00065	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CSK—systemic scleroderma	0.000173	0.00064	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—CTGF—systemic scleroderma	0.000165	0.00061	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—CTGF—systemic scleroderma	0.000165	0.00061	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—CTGF—systemic scleroderma	0.000165	0.00061	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—CTGF—systemic scleroderma	0.000162	0.000601	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HLA-DQB1—systemic scleroderma	0.000159	0.000589	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HLA-DQB1—systemic scleroderma	0.000159	0.000589	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HLA-DQB1—systemic scleroderma	0.000159	0.000589	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HLA-DQB1—systemic scleroderma	0.000157	0.000581	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	0.000152	0.000562	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL1A—systemic scleroderma	0.000151	0.00056	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL1A—systemic scleroderma	0.000151	0.00056	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL1A—systemic scleroderma	0.000151	0.00056	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CD40LG—systemic scleroderma	0.00015	0.000557	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CD40LG—systemic scleroderma	0.00015	0.000557	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CD40LG—systemic scleroderma	0.00015	0.000557	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL1A—systemic scleroderma	0.000149	0.000552	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CD40LG—systemic scleroderma	0.000148	0.000549	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—EDN1—systemic scleroderma	0.00013	0.00048	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EDN1—systemic scleroderma	0.000129	0.000478	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—NOS3—systemic scleroderma	0.000113	0.000418	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—NOS3—systemic scleroderma	0.000112	0.000416	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL1B—systemic scleroderma	0.000104	0.000385	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL1B—systemic scleroderma	0.000104	0.000383	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EDN1—systemic scleroderma	9.84e-05	0.000364	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EDN1—systemic scleroderma	9.84e-05	0.000364	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EDN1—systemic scleroderma	9.84e-05	0.000364	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EDN1—systemic scleroderma	9.7e-05	0.000359	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—NOS3—systemic scleroderma	9.46e-05	0.00035	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—NOS3—systemic scleroderma	9.41e-05	0.000348	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CCL2—systemic scleroderma	8.87e-05	0.000328	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CCL2—systemic scleroderma	8.83e-05	0.000327	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—NOS3—systemic scleroderma	8.56e-05	0.000317	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—NOS3—systemic scleroderma	8.56e-05	0.000317	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—NOS3—systemic scleroderma	8.56e-05	0.000317	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—NOS3—systemic scleroderma	8.44e-05	0.000312	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—NOS3—systemic scleroderma	7.91e-05	0.000293	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL1B—systemic scleroderma	7.89e-05	0.000292	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL1B—systemic scleroderma	7.89e-05	0.000292	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL1B—systemic scleroderma	7.89e-05	0.000292	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—NOS3—systemic scleroderma	7.87e-05	0.000291	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL1B—systemic scleroderma	7.78e-05	0.000288	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	7.5e-05	0.000278	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—TGFB1—systemic scleroderma	7.47e-05	0.000276	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—TGFB1—systemic scleroderma	7.43e-05	0.000275	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—NOS3—systemic scleroderma	7.17e-05	0.000265	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—NOS3—systemic scleroderma	7.17e-05	0.000265	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—NOS3—systemic scleroderma	7.17e-05	0.000265	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—NOS3—systemic scleroderma	7.07e-05	0.000262	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCL2—systemic scleroderma	6.72e-05	0.000249	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCL2—systemic scleroderma	6.72e-05	0.000249	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCL2—systemic scleroderma	6.72e-05	0.000249	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCL2—systemic scleroderma	6.63e-05	0.000245	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HSPG2—systemic scleroderma	6.39e-05	0.000237	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MMP9—systemic scleroderma	6.34e-05	0.000235	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MMP9—systemic scleroderma	6.31e-05	0.000234	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NOS3—systemic scleroderma	5.99e-05	0.000222	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NOS3—systemic scleroderma	5.99e-05	0.000222	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NOS3—systemic scleroderma	5.99e-05	0.000222	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NOS3—systemic scleroderma	5.91e-05	0.000219	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—TGFB1—systemic scleroderma	5.66e-05	0.000209	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—TGFB1—systemic scleroderma	5.66e-05	0.000209	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—TGFB1—systemic scleroderma	5.66e-05	0.000209	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—TGFB1—systemic scleroderma	5.58e-05	0.000207	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TGFB1—systemic scleroderma	5.23e-05	0.000194	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TGFB1—systemic scleroderma	5.2e-05	0.000193	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CTGF—systemic scleroderma	4.84e-05	0.000179	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MMP9—systemic scleroderma	4.81e-05	0.000178	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MMP9—systemic scleroderma	4.81e-05	0.000178	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MMP9—systemic scleroderma	4.81e-05	0.000178	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MMP9—systemic scleroderma	4.74e-05	0.000175	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TGFB1—systemic scleroderma	3.96e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TGFB1—systemic scleroderma	3.96e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TGFB1—systemic scleroderma	3.96e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TGFB1—systemic scleroderma	3.91e-05	0.000145	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NOS3—systemic scleroderma	2.11e-05	7.81e-05	CbGpPWpGaD
